Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.50 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14266579 | 0.93 | CSF1R (0.49) | BRAFRAF1KDRKMT2A | |
| SCHEMBL3992270 | 0.89 | MAPK8 (0.56) | — | |
| SCHEMBL3988798 | 0.88 | BRAF (0.48) | BRAFRAF1KDRFDFT1KMT2A | |
| SCHEMBL14266590 | 0.87 | KDR (0.53) | BRAFRAF1KDRFDFT1KMT2A | |
| SCHEMBL3991259 | 0.87 | BRAF (0.48) | BRAFRAF1KDRKDM4ERET | |
| SCHEMBL5115902 | 0.87 | CSF1R (0.48) | BRAFRAF1KDRRET | |
| SCHEMBL14266573 | 0.85 | CSF1R (0.54) | BRAFRAF1KDRGAA | |
| SCHEMBL3991170 | 0.85 | BRAF (0.51) | BRAFRAF1KDRRET | |
| SCHEMBL14266603 | 0.85 | CSF1R (0.49) | BRAFRAF1KDRGAAKDM4E | |
| SCHEMBL5123391 | 0.84 | RAF1 (0.53) | BRAFRAF1KDRGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061761-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | Millennium Pharmaceuticals, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2008030448-A1 | PHENETHYLAMIDE DERIVATIVES WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064729-A1 | Phenethylamide derivatives with kinase inhibitory activity | MAP4K5, MAP3K5, MAP4K2 | BRAF 242/4885RAF1 251/4885KDR 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.